Increased serum level of epidermal growth factor receptor (EGFR) is associated with poor progression-free survival in patients with epithelial ovarian cancer


Tas F. , Karabulut S., Serilmez M. , Ciftci R., Duranyildiz D.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.73, no.3, pp.631-637, 2014 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 73 Issue: 3
  • Publication Date: 2014
  • Doi Number: 10.1007/s00280-014-2396-x
  • Title of Journal : CANCER CHEMOTHERAPY AND PHARMACOLOGY
  • Page Numbers: pp.631-637

Abstract

Epidermal growth factor receptor (EGFR) plays an important role in the pathogenesis of multiple malignancies, and its expression also strongly affects the outcomes of cancer patients. The objective of this study was to determine the clinical significance of the serum levels of EGFR in epithelial ovarian cancer (EOC) patients.